Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Agenix has entered two strategic agreements with its partners in China to commercialise new drug candidates and complete pre-clinical toxicology tests for its new hepatitis B drug in China.
Subscribe to our email newsletter
The company inked a deal with Institute of Pharmacology and Toxicology of the Academy of Military Medical Sciences in China to complete final toxicology tests for AGX-1009, a hepatitis B compound.
A memorandum of understanding between Agenix and the Institute of Medicinal Biotechnology (IMB) of the Chinese Academy of Medical Sciences, covers development of future drug candidates, besides production and marketing.
Agenix Chairman and CEO Nicholas Weston said the deal would strengthen their commercial position in China.